儿童CKD进展的血浆代谢物生物标志物
研究对645例CKiD参与者进行非靶向血浆代谢组学分析,评估825种非药物代谢物与CKD进展的关联。中位随访4.8年,209例(32%)发生复合结局;在基线eGFR≥60亚组中发现7种代谢物与更高风险相关,基线eGFR<60亚组中四氢皮质醇硫酸盐水平较高与风险降低相关。
要点
- 儿童CKD患者中,特定血浆代谢物与KRT或eGFR减半风险独立相关。
- 基线eGFR≥60者,7种代谢物(如假尿苷HR 39)与进展风险升高相关。
- 基线eGFR<60者,四氢皮质醇硫酸盐较高与进展风险降低相关(HR 0.8)。
核心结论
- 非靶向血浆代谢组学发现与儿童CKD进展独立相关的新代谢物,提示特定生物通路的作用。
研究设计与样本
- 对645例CKiD参与者的储存血浆样本进行非靶向代谢组学定量,代谢物经标准化和对数转换。
- 采用Cox比例风险回归分析825种非药物代谢物与复合结局(KRT或eGFR降低50%)的关联,并校正年龄、性别、种族、BMI、高血压、诊断类型、蛋白尿和基线eGFR。
主要发现
- 中位随访4.8年,209例(32%)发生复合结局;基线中位年龄12岁,中位eGFR 54 ml/min per 1.73 m2,448例(69%)为非肾小球诊断。
- 基线eGFR≥60 ml/min per 1.73 m2者中,7种代谢物水平翻倍与KRT/eGFR减半风险显著升高相关:N6-氨甲酰苏氨酰腺苷HR 16(95%CI 4-60)、5,6-二氢尿苷HR 17(95%CI 5-55)、假尿苷HR 39(95%CI 8-200)、C-糖基色氨酸HR 24(95%CI 6-95)、羊毛硫氨酸HR 3(95%CI 2-5)、2-甲基柠檬酸/同柠檬酸HR 4(95%CI 2-7)、古洛糖酸HR 10(95%CI 3-29)。
- 基线eGFR<60 ml/min per 1.73 m2者中,四氢皮质醇硫酸盐水平较高与进展风险降低相关(HR 0.8;95%CI 0.7-0.9)。
临床怎么用
- 这些代谢物可能作为儿童CKD进展的候选生物标志物,但需外部验证后方可用于临床风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Metabolomics facilitates the discovery of biomarkers and potential therapeutic targets for CKD progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated an untargeted metabolomics quantification of stored plasma samples from 645 Chronic Kidney Disease in Children (CKiD) participants. Metabolites were standardized and logarithmically transformed. Cox proportional hazards regression examined the association between 825 nondrug metabolites and progression to the composite outcome of KRT or 50% reduction of eGFR, adjusting for age, sex, race, body mass index, hypertension, glomerular versus nonglomerular diagnosis, proteinuria, and baseline eGFR. Stratified analyses were performed within subgroups of glomerular/nonglomerular diagnosis and baseline eGFR. RESULTS: Baseline characteristics were 391 (61%) male; median age 12 years; median eGFR 54 ml/min per 1.73 m2; 448 (69%) nonglomerular diagnosis. Over a median follow-up of 4.8 years, 209 (32%) participants developed the composite outcome. Unique association signals were identified in subgroups of baseline eGFR. Among participants with baseline eGFR ≥60 ml/min per 1.73 m2, two-fold higher levels of seven metabolites were significantly associated with higher hazards of KRT/halving of eGFR events: three involved in purine and pyrimidine metabolism (N6-carbamoylthreonyladenosine, hazard ratio, 16; 95% confidence interval, 4 to 60; 5,6-dihydrouridine, hazard ratio, 17; 95% confidence interval, 5 to 55; pseudouridine, hazard ratio, 39; 95% confidence interval, 8 to 200); two amino acids, C-glycosyltryptophan, hazard ratio, 24; 95% confidence interval 6 to 95 and lanthionine, hazard ratio, 3; 95% confidence interval, 2 to 5; the tricarboxylic acid cycle intermediate 2-methylcitrate/homocitrate, hazard ratio, 4; 95% confidence interval, 2 to 7; and gulonate, hazard ratio, 10; 95% confidence interval, 3 to 29. Among those with baseline eGFR <60 ml/min per 1.73 m2, a higher level of tetrahydrocortisol sulfate was associated with lower risk of progression (hazard ratio, 0.8; 95% confidence interval, 0.7 to 0.9). CONCLUSIONS: Untargeted plasma metabolomic profiling facilitated discovery of novel metabolite associations with CKD progression in children that were independent of established clinical predictors and highlight the role of select biologic pathways.
引用
- Denburg MR, Xu Y, Abraham AG, et al. Metabolite Biomarkers of CKD Progression in Children. Clin J Am Soc Nephrol. 2021. PMID: 34362785. doi:10.2215/CJN.00220121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。